Beneficio del empleo precoz de la oxigenoterapia nasal de alto flujo (ONAF) en pacientes con neumonía por SARS-CoV-2

INTRODUCTION: Severe COVID-19 is associated with hypoxemic bilateral pneumonia that leads to mechanical ventilation in a considerable proportion of patients. To the best of our knowledge, there are no recommendations about the best time to initiate high flow nasal cannula (HFNC). PATIENTS AND METHOD...

Descripción completa

Detalles Bibliográficos
Autores principales: García-Pereña, Laura, Ramos Sesma, Violeta, Tornero Divieso, María Lucía, Lluna Carrascosa, Alfonso, Velasco Fuentes, Sara, Parra-Ruiz, Jorge
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier España, S.L.U. 2022
Materias:
Original Breve
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8206615/
https://www.ncbi.nlm.nih.gov/pubmed/34218943
http://dx.doi.org/10.1016/j.medcli.2021.05.015
Descripción
Sumario:INTRODUCTION: Severe COVID-19 is associated with hypoxemic bilateral pneumonia that leads to mechanical ventilation in a considerable proportion of patients. To the best of our knowledge, there are no recommendations about the best time to initiate high flow nasal cannula (HFNC). PATIENTS AND METHODS: Retrospective study of all patients admitted for COVID-19 pneumonia who required HNFO between March 2020 and February 2021. Patients were grouped in early HNFC or late HNFC, according to the modified Kirby index. RESULTS: 53 patients were included. Forty-four of them were included in the early HFNC and 9 in late HNFC. There were no statistically significant clinical-epidemiological differences. Early use of HFNC was associated with a decrease in the need for intubation (29.5 vs. 66.6%, p = 0.044), hospital stay (18.8 d vs. 36 d, p = 0.022) and mortality (22.7 vs. 55.5%, p = 0.061). CONCLUSIONS: Early HFNC use is associated with a decrease in the need for intubation, mortality and overall hospital stay.

Ejemplares similares